Achillion Pharmaceuticals Valuation

Achillion Pharmaceuticals Investor Information

About 98.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.0. Achillion Pharmaceuticals had not issued any dividends in recent years. Based on the key indicators related to Achillion Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Achillion Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in December.

Achillion Pharmaceuticals Asset Utilization

The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Achillion Pharmaceuticals has an asset utilization ratio of 0.001873 percent. This suggests that the Company is making $1.9E-5 for each dollar of assets. An increasing asset utilization means that Achillion Pharmaceuticals is more efficient with each dollar of assets it utilizes for everyday operations.

Achillion Pharmaceuticals Ownership Allocation

Achillion Pharmaceuticals holds a total of 30 Million outstanding shares. Achillion Pharmaceuticals shows majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company's outstanding shares. 97.61 percent of Achillion Pharmaceuticals outstanding shares that are owned by insiders signifies that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Achillion Pharmaceuticals Profitability Analysis

The company reported the previous year's revenue of 8.7 K. Net Loss for the year was (51 K) with profit before overhead, payroll, taxes, and interest of 7.87 K.

Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.

Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.

If you are still planning to invest in Achillion Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Achillion Pharmaceuticals' history and understand the potential risks before investing.